Search Results - "NEGRAO, Marcelo V"

Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives by Lee, Jay M, McNamee, Ciaran J, Toloza, Eric, Negrao, Marcelo V, Lin, Jules, Shum, Elaine, Cummings, Amy L, Kris, Mark G, Sepesi, Boris, Bara, Ilze, Kurtsikidze, Nino, Schulze, Katja, Ngiam, Celina, Chaft, Jamie E

“…The standard of care (SoC) for medically operable patients with early-stage (stages I-IIIB) NSCLC is surgery combined with (neo)adjuvant systemic therapy for…”
Get more information

Author Correction: BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape by Planchard, David, Sanborn, Rachel E., Negrao, Marcelo V., Vaishnavi, Aria, Smit, Egbert F.

Get full text

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape by Planchard, David, Sanborn, Rachel E., Negrao, Marcelo V., Vaishnavi, Aria, Smit, Egbert F.

“…In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and…”
Get full text

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort by Mitchell, Kyle G, Diao, Lixia, Karpinets, Tatiana, Negrao, Marcelo V, Tran, Hai T, Parra, Edwin R, Corsini, Erin M, Reuben, Alexandre, Federico, Lorenzo, Bernatchez, Chantale, Dejima, Hitoshi, Francisco-Cruz, Alejandro, Wang, Jing, Antonoff, Mara B, Vaporciyan, Ara A, Swisher, Stephen G, Cascone, Tina, Wistuba, Ignacio I, Heymach, John V, Gibbons, Don L, Zhang, Jianjun, Haymaker, Cara L, Sepesi, Boris

“…BackgroundThe biological underpinnings of the prognostic and predictive significance of a relative neutrophilia in patients with non-small lung cancer (NSCLC)…”
Get full text

Breast Cancer Promotes Cardiac Dysfunction Through Deregulation of Cardiomyocyte Ca2+-Handling Protein Expression That is Not Reversed by Exercise Training by da Costa, Tassia S R, Urias, Ursula, Negrao, Marcelo V, Jordão, Camila P, Passos, Clévia S, Gomes-Santos, Igor L, Salemi, Vera Maria C, Camargo, Anamaria A, Brum, Patricia C, Oliveira, Edilamar M, Hajjar, Ludhmila A, Chammas, Roger, Filho, Roberto K, Negrao, Carlos E

“…Background Patients treated for breast cancer have a high incidence of cardiovascular complications. In this study, we evaluated the impact of breast cancer on…”
Get full text

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation by Jänne, Pasi A., Riely, Gregory J., Gadgeel, Shirish M., Heist, Rebecca S., Ou, Sai-Hong I., Pacheco, Jose M., Johnson, Melissa L., Sabari, Joshua K., Leventakos, Konstantinos, Yau, Edwin, Bazhenova, Lyudmila, Negrao, Marcelo V., Pennell, Nathan A., Zhang, Jun, Anderes, Kenna, Der-Torossian, Hirak, Kheoh, Thian, Velastegui, Karen, Yan, Xiaohong, Christensen, James G., Chao, Richard C., Spira, Alexander I.

“…Adagrasib produced responses in 43% of previously treated patients with non–small-cell lung cancer containing a KRAS G12C mutation, with median overall…”
Get full text

Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC by Negrao, Marcelo V., Papadimitrakopoulou, Vassiliki A., Price, Andrew C., Tam, Alda L., Furqan, Muhammad, Laroia, Sandeep T., Massarelli, Erminia, Pacheco, Jose, Heymach, John V., Tsao, Anne S., Walker, Gary V., Vora, Lalit, Mauro, David, Kelley, Heather, Wooldridge, James E., Krieg, Arthur M., Niu, Jiaxin

“…Vidutolimod, a CpG-A TLR9 agonist, was investigated in a phase 1b study (CMP-001-003; ClinicalTrials.gov, NCT03438318) in combination with atezolizumab with…”
Get full text

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC by Le, Xiuning, Puri, Sonam, Negrao, Marcelo V, Nilsson, Monique B, Robichaux, Jacqulyne, Boyle, Theresa, Hicks, J Kevin, Lovinger, Katherine L, Roarty, Emily, Rinsurongkawong, Waree, Tang, Ming, Sun, Huiying, Elamin, Yasir, Lacerda, Lara C, Lewis, Jeff, Roth, Jack A, Swisher, Stephen G, Lee, J Jack, William, Jr, William N, Glisson, Bonnie S, Zhang, Jianjun, Papadimitrakopoulou, Vassiliki A, Gray, Jhanelle E, Heymach, John V

“…Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of -mutant NSCLC…”
Get full text

STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition by Sitthideatphaiboon, Piyada, Galan-Cobo, Ana, Negrao, Marcelo V, Qu, Xiao, Poteete, Alissa, Zhang, Fahao, Liu, Diane D, Lewis, Whitney E, Kemp, Haley N, Lewis, Jeff, Rinsurongkawong, Waree, Giri, Uma, Lee, J Jack, Zhang, Jianjun, Roth, Jack A, Swisher, Stephen, Heymach, John V

“…Radiotherapy with or without chemotherapy is a mainstay of treatment for locally advanced non-small cell lung cancer (NSCLC), but no predictive markers are…”
Get full text

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases by Negrao, Marcelo V, Spira, Alexander I, Heist, Rebecca S, Jänne, Pasi A, Pacheco, Jose M, Weiss, Jared, Gadgeel, Shirish M, Velastegui, Karen, Yang, Wenjing, Der-Torossian, Hirak, Christensen, James G, Sabari, Joshua K

“…Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be…”
Get full text

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial by Elamin, Yasir Y, Robichaux, Jacqulyne P, Carter, Brett W, Altan, Mehmet, Gibbons, Don L, Fossella, Frank V, Lam, Vincent K, Patel, Anisha B, Negrao, Marcelo V, Le, Xiuning, Mott, Frank E, Zhang, Jianjun, Feng, Lei, Blumenschein, Jr, George, Tsao, Anne S, Heymach, John V

“…Targeted therapies against non-small-cell lung cancer (NSCLC) harboring mutations remain an unmet need. In this study, we assessed the efficacy and safety of…”
Get full text

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype by Della Corte, Carminia M, Sen, Triparna, Gay, Carl M, Ramkumar, Kavya, Diao, Lixia, Cardnell, Robert J, Rodriguez, Bertha Leticia, Stewart, C Allison, Papadimitrakopoulou, Vassiliki A, Gibson, Laura, Fradette, Jared J, Wang, Qi, Fan, Youhong, Peng, David H, Negrao, Marcelo V, Wistuba, Ignacio I, Fujimoto, Junya, Solis Soto, Luisa M, Behrens, Carmen, Skoulidis, Ferdinandos, Heymach, John V, Wang, Jing, Gibbons, Don L, Byers, Lauren A

“…Although the combination of anti-programmed cell death-1 or anti-programmed cell death ligand-1 (PD-L1) with platinum chemotherapy is a standard of care for…”
Get more information

Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer by Sepesi, Boris, Zhou, Nicolas, William, William N., Lin, Heather Y., Leung, Cheuk H., Weissferdt, Annikka, Mitchell, Kyle G., Pataer, Apar, Walsh, Garrett L., Rice, David C., Roth, Jack A., Mehran, Reza J., Hofstetter, Wayne L., Antonoff, Mara B., Rajaram, Ravi, Negrao, Marcelo V., Tsao, Anne S., Gibbons, Don L., Lee, J. Jack, Heymach, John V., Vaporciyan, Ara A., Swisher, Stephen G., Cascone, Tina

“…Surgical outcomes for non–small cell lung cancer after neoadjuvant immune checkpoint inhibitors continue to be debated. We assessed perioperative outcomes of…”
Get full text

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity by Elamin, Yasir Y., Robichaux, Jacqulyne P., Carter, Brett W., Altan, Mehmet, Tran, Hai, Gibbons, Don L., Heeke, Simon, Fossella, Frank V., Lam, Vincent K., Le, Xiuning, Negrao, Marcelo V., Nilsson, Monique B., Patel, Anisha, Vijayan, R.S.K., Cross, Jason B., Zhang, Jianjun, Byers, Lauren A., Lu, Charles, Cascone, Tina, Feng, Lei, Luthra, Rajyalakshmi, San Lucas, Francis A., Mantha, Geeta, Routbort, Mark, Blumenschein, George, Tsao, Anne S., Heymach, John V.

“…We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with point mutations or insertions in EGFR exon 20 treated with…”
Get full text

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer by Negrao, Marcelo V, Skoulidis, Ferdinandos, Montesion, Meagan, Schulze, Katja, Bara, Ilze, Shen, Vincent, Xu, Hao, Hu, Sylvia, Sui, Dawen, Elamin, Yasir Y, Le, Xiuning, Goldberg, Michael E, Murugesan, Karthikeyan, Wu, Chang-Jiun, Zhang, Jianhua, Barreto, David S, Robichaux, Jacqulyne P, Reuben, Alexandre, Cascone, Tina, Gay, Carl M, Mitchell, Kyle G, Hong, Lingzhi, Rinsurongkawong, Waree, Roth, Jack A, Swisher, Stephen G, Lee, Jack, Tsao, Anne, Papadimitrakopoulou, Vassiliki, Gibbons, Don L, Glisson, Bonnie S, Singal, Gaurav, Miller, Vincent A, Alexander, Brian, Frampton, Garrett, Albacker, Lee A, Shames, David, Zhang, Jianjun, Heymach, John V

“…BackgroundNon-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade…”
Get full text

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target by Le, Xiuning, Negrao, Marcelo V, Reuben, Alexandre, Federico, Lorenzo, Diao, Lixia, McGrail, Daniel, Nilsson, Monique, Robichaux, Jacqulyne, Munoz, Irene Guijarro, Patel, Sonia, Elamin, Yasir, Fan, You-Hong, Lee, Won-Chul, Parra, Edwin, Solis Soto, Luisa Maren, Chen, Runzhe, Li, Jun, Karpinets, Tatiana, Khairullah, Roohussaba, Kadara, Humam, Behrens, Carmen, Sepesi, Boris, Wang, Ruiping, Zhu, Mingrui, Wang, Linghua, Vaporciyan, Ara, Roth, Jack, Swisher, Stephen, Haymaker, Cara, Zhang, Jianhua, Wang, Jing, Wong, Kwok-Kin, Byers, Lauren A, Bernatchez, Chantale, Zhang, Jianjun, Wistuba, Ignacio I, Gibbons, Don L, Akbay, Esra A, Heymach, John V

“…Lung adenocarcinomas harboring EGFR mutations do not respond to immune checkpoint blockade therapy and their EGFR wildtype counterpart. The mechanisms…”
Get more information

Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC by Gaudreau, Pierre-Olivier, Negrao, Marcelo V, Mitchell, Kyle G, Reuben, Alexandre, Corsini, Erin M, Li, Jun, Karpinets, Tatiana V, Wang, Qi, Diao, Lixia, Wang, Jing, Federico, Lorenzo, Parra-Cuentas, Edwin R, Khairullah, Roohussaba, Behrens, Carmen, Correa, Arlene M, Gomez, Daniel, Little, Latasha, Gumbs, Curtis, Kadara, Humam N, Fujimoto, Junya, McGrail, Daniel J, Vaporciyan, Ara A, Swisher, Stephen G, Walsh, Garrett, Antonoff, Mara B, Weissferdt, Annikka, Tran, Hai, Roarty, Emily, Haymaker, Cara, Bernatchez, Chantale, Zhang, Jianhua, Futreal, P Andrew, Wistuba, Ignacio I, Cascone, Tina, Heymach, John V, Sepesi, Boris, Zhang, Jianjun, Gibbons, Don L

“…The combination of programmed cell death protein-1 or programmed death-ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the treatment of…”
Get more information

Noninvasive genomic profiling of somatic mutations in oral cavity cancers by Xi, Yuanxin, Negrao, Marcelo V., Akagi, Keiko, Xiao, Weihong, Jiang, Bo, Warner, Sarah C., Dunn, Joe Dan, Wang, Jing, Symer, David E., Gillison, Maura L.

“…•Evaluation of genetic profiling of oral rinse samples as surrogates for oral cancers.•Assay comprised targeted sequencing of 42 genes frequently mutated in…”
Get full text

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC by Vokes, Natalie I, Galan Cobo, Ana, Fernandez-Chas, Margarita, Molkentine, David, Treviño, 3rd, Santiago, Druker, Vitaly, Qian, Yu, Patel, Sonia, Schmidt, Stephanie, Hong, Lingzhi, Lewis, Jeff, Rinsurongkawong, Waree, Rinsurongkawong, Vadeerat, Lee, J Jack, Negrao, Marcelo V, Gibbons, Don L, Vaporciyan, Ara, Le, Xiuning, Wu, Jia, Zhang, Jianjun, Rigney, Una, Iyer, Sonia, Dean, Emma, Heymach, John V

“…Ataxia-telangiectasia mutated (ATM) is the most frequently mutated DNA damage repair gene in non-small cell lung cancer (NSCLC). However, the molecular…”
Get full text

An atlas of epithelial cell states and plasticity in lung adenocarcinoma by Han, Guangchun, Sinjab, Ansam, Rahal, Zahraa, Lynch, Anne M., Treekitkarnmongkol, Warapen, Liu, Yuejiang, Serrano, Alejandra G., Feng, Jiping, Liang, Ke, Khan, Khaja, Lu, Wei, Hernandez, Sharia D., Liu, Yunhe, Cao, Xuanye, Dai, Enyu, Pei, Guangsheng, Hu, Jian, Abaya, Camille, Gomez-Bolanos, Lorena I., Peng, Fuduan, Chen, Minyue, Parra, Edwin R., Cascone, Tina, Sepesi, Boris, Moghaddam, Seyed Javad, Scheet, Paul, Negrao, Marcelo V., Heymach, John V., Li, Mingyao, Dubinett, Steven M., Stevenson, Christopher S., Spira, Avrum E., Fujimoto, Junya, Solis, Luisa M., Wistuba, Ignacio I., Chen, Jichao, Wang, Linghua, Kadara, Humam

“…Understanding the cellular processes that underlie early lung adenocarcinoma (LUAD) development is needed to devise intervention strategies 1 . Here we studied…”
Get full text